[TIM3+CD8+ T Cell Expression and Clinical Significance in the Central and Non-central Tumor Microenvironment of Non-small Cell Lung Cancer] [0.03%]
非小细胞肺癌肿瘤中心和非中心区域TIM3+CD8+T细胞的表达及其临床意义
Jiajuan Wu,Shiying Guo,Leilei Lv et al.
Jiajuan Wu et al.
Background: One of the most important treatment modalities for non-small cell lung cancer (NSCLC) is immune checkpoint inhibitor. Nevertheless, a small percentage of patients do not respond well to these therapies, highli...
[Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study] [0.03%]
支气管肺泡灌洗液免疫细胞亚群与晚期非小细胞肺癌一线使用免疫治疗疗效相关性分析：一项病例对照研究
Kai Zhang,Liang Shi,Tongmei Zhang et al.
Kai Zhang et al.
Background: Immunotherapy has been a standard treatment for the patients with advanced non-small cell lung cancer (NSCLC), however, reliable biomarkers for predicting the response remain unclear. This study explores the s...
Qingxia Hou,Yingmei Wang,Meng Cao et al.
Qingxia Hou et al.
Background: Numerous researches indicated that electromagnetic pulses (EMP) possessed advantages such as strong targeting, minimal side-effects and low treatment cost in tumor therapy, but its optimum parameters for treat...
[A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified Lung Squamous Cell Carcinoma and Literature Review] [0.03%]
EGFR-TKIs继发耐药MET基因扩增肺鳞癌一例及文献复习
Yalan Liu,Peng Chen,Xinfu Liu
Yalan Liu
With the rapid development of epidermal growth factor receptor (EGFR) gene testing of lung adenocarcinoma patients has been routinely carried out, EGFR mutations are also possible for some small samples of non-smoking female lung squamous c...
[Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification: A Case Report] [0.03%]
卡梅替尼诱导的非小细胞肺癌伴MET扩增病理完全缓解一例报告
Meng Lu,Ran Zhang,Baiwei Li et al.
Meng Lu et al.
Mesenchymal-epithelial transition factor (MET) gene mutation is a large class of mutations commonly seen in non-small cell lung cancer (NSCLC). MET mutation includes subtypes such as MET exon 14 skipping mutation (METex14m) and MET amplific...
[Application of Nano-drug Delivery Technology in Overcoming Drug Resistance in Lung Cancer] [0.03%]
纳米药物输送技术在克服肺癌耐药性中应用研究
Yingchun Lu,Chunyu Wang,Bin Liu
Yingchun Lu
Lung cancer is one of the most malignant tumor, representing a significant threat to human health. In China, its mortality rate is the highest among all malignant tumors. The occurrence of drug resistance has resulted in unfavourable progno...
[Immunotherapy for Extensive-stage Small Cell Lung Cancer: Research Progress and Future Perspectives] [0.03%]
广泛期小细胞肺癌免疫治疗研究进展及未来展望
Yuling Zhong,Jingyi Wang,Lin Wu
Yuling Zhong
At present, immunotherapy combined with chemotherapy has become the first-line standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). In recent years, immune checkpoint inhibitors (ICIs) have received extensive attentio...
[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer] [0.03%]
ALK阳性非小细胞肺癌新辅助靶向治疗研究进展
Weizhen Sun,Yuheng Zhou,Yaobin Lin et al.
Weizhen Sun et al.
Lung cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death worldwide, with anaplastic lymphoma kinase (ALK) fusion mutations accounting for approximately 4%-9% of cases. In recent years, there are...
[Clinicopathological Analysis of 14 Cases of Primary Pulmonary Lymphoepithelial Carcinoma] [0.03%]
原发肺淋巴上皮瘤样癌临床病理分析14例
Yixuan Fang,Anzhe Wang,Lumin Shen et al.
Yixuan Fang et al.
Background: Primary pulmonary lymphoepithelial carcinoma (PPLEC) is a rare form of lung malignancy, accounting for only 0.7% of all lung cancers. It is currently classified as a distinct subtype within squamous cell carci...
[Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer] [0.03%]
【放疗联合免疫和化疗改善广泛期小细胞肺癌预后并产生协同效应】
Huaijun Ji,Meiling Sun,Jingyi Li et al.
Huaijun Ji et al.
Background: Extensive-stage small cell lung cancer (ES-SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. This study ...